The Eu2P project was set up to respond to the growing need for well-trained professionals, specialists and non-specialists, in pharmacovigilance and pharmacoepidemiology. Pharmacovigilance involves collecting and analysing information from patients and health care providers on potential adverse effect of medications that are already on the market. In pharmacoepidemiology, scientists study, predict and compare the risks and benefits of commercial or experimental medicines in populations.
By bringing together 7 academic, 2 regulatory and 15 industry partners, the Eu2P project developed the first pan-European, internationally recognised programmes in pharmacovigilance and pharmacoepidemiology. Through the Eu2P on-line platform, which can be accessed anytime and anywhere, it offers courses which lead to a joint master’s degree, a PhD degree, 25 joint academic certificates and over 50 short courses. Specialisations include topics such benefit assessment of medicines, medicines risk identification and quantification, and medicines risk communication. The programmes target specialists such as pharmacists, physicians, scientists and experienced professionals, but also non specialists such as journalists, lay people, and patients. More than 2 500 course registrations have already been recorded for its short courses and almost 500 people have attended Eu2P’s postgraduate programmes. About 15 % of students so far came from lower income countries (e.g. from Africa and Asia). For them, a limited number of partial grants are available.
The emphasis is put on ‘hands-on training’ to maximise post-training employment opportunities. The courses are delivered in English using a unique and innovative modular approach which integrates multimedia lessons, video conferences, online quizzes and assignments.
Benefits for academia and industry
Six European universities, part of Eu2P, are now offering Eu2P joint certificates and postgraduate programmes in pharmacovigilance and pharmaceopidemology. The establishment of these programmes raised their profile and recognition on an international level. The public partners in the project also benefited from the network and collaborations established during Eu2P.
Thanks to the project, industry employees can now get internationally recognised postgraduate certificate diplomas, master’s and PhD degrees, as well as academically recognised short courses which have been tailored to their needs.
After the project ended in June 2016, six of the universities which were part of the project and five private partners signed a memorandum of understanding to continue the project. The programmes and courses offered are now self-sustainable, and are funded through student fees. Courses are being continuously updated as the field evolves, and additional courses are planned.
Read the interview with project coordinators
Achievements & News
Born out of an IMI project, EU2P have offered a growing suite of certified drug-safety education courses since 2009. They are now expanding beyond the EU.###
EU2P was set up to provide a pan-European, fully-accredited (and EU-wide recognised) training programme that could supply the skills and qualifications needed for a growing and evolving field. The number and variety of courses on offer by EU2P have steadily grown, and they span the quick and generic, such as a two-hour online course on drug safety basics, to a European Masters and PhD programme. The programme is still managed by the original team, based in the Université de Bordeaux.
‘The enduring success of the programme is due to the continuous investment in the development of new courses according to the demand of pharmaceutical companies and international scientific societies,’ programme manager Karine Palin told the IMI Programme Office. ‘The crucial element is that trainees benefit from academic accreditation and therefore can be awarded ECTS (European credit transfer and accumulation system) credits following their assessment.’
Looking to the future, the EU2P team is now developing courses in drug safety targeting the North American pharmaceutical industry, with a new programme called Am2P (for American Program in Pharmacovigilance).
Find out more
- Read the article in full
Eu2P developed the first internationally recognised European online education & training programmes in pharmacovigilance and pharmacoepidemiology. In an interview with the IMI Programme Office, academic project coordinator Annie Fourrier-Réglat and project manager Karine Palin, both of the University of Bordeaux, reveal the long-lasting benefits that this project will bring to academia and industry. ### ‘All this wouldn’t have been possible without the IMI funding and collaboration between the different partners in the public and private sectors,’ said Fourrier-Réglat. Read the full interview
Registration is now open for the Eu2P Master programme in pharmacovigilance and pharmacoepidemiology for the academic year 2017-2018. The Eu2P Master is an academic post-graduate training that leads to an MSc degree jointly awarded by the six European Universities working together as Eu2P partners.### The deadline for applications is 25 June 2017. IMI’s Eu2P project runs numerous courses covering various aspects of medicines research and development, including pharmacovigilance. The courses range from short, ‘bite-sized’ online courses to full Master’s programmes. Details of all courses offered as well as information on how to apply can be found on the project website.
IMI’s Eu2P project runs numerous courses covering various aspects of medicines research and development, including pharmacovigilance. The courses range from short, ‘bite-sized’ online courses to full Master’s programmes. ###Now the project has produced a handy ‘at a glance’ guide that provides students with a simple overview of the types of courses available, the workload involved, and the certificates offered upon successful completion of the course. Applications for the short online courses are always open. The deadline for applications for the next intake of Masters students is 26 June. The Eu2P Master is an academic post-graduate training in pharmacovigilance and pharmacoepidemiology that leads to a MSc degree jointly awarded by the European Universities working together as Eu2P partners. Finally, the next deadlines for applying for the shorter certificates are in early September.
IMI education and training project Eu2P has officially launched short online courses in pharmacovigilance. The courses take account of healthcare professionals’ and organisations training needs and the fact that students may have limited study time.### As such, they consist of self-paced learning activities (the average work load per course is under two hours) followed by a final evaluation test. Students who pass the test receive a certificate of training achievement.
Eu2P has short courses covering a range of areas, including safety, benefit-risk assessments, pharmacovigilance, and public health. Courses are built and recognised by the project’s academic, regulatory and industrial partners, meaning that the content is grounded in the real world.
Registration is now open for the Eu2P Master programme in pharmacovigilance and pharmacoepidemiology for the academic year 2014-2015. According to the project, there are four reasons to sign up for the programme.###
- Get a European academic Masters degree
The Eu2P Master is an academic post-graduate diploma in pharmacovigilance and pharmacoepidemiology jointly delivered by the seven European academic bodies working together as Eu2P partners.
- Get a job market proof diploma
The Eu2P European Master is built and recognised by all the 24 academic, regulatory and industrial Eu2P partners. Eu2P courses are grounded in the real job market and today's practices and research projects can be performed in public or private environments.
- Choose a flexible online programme
Awarded for the quality of the e-learning experience, Eu2P online courses can be attended at home or at work and full time or part time.
- Build your curriculum specialisation
In your second year, you can choose to specialise in a specific field or select ‘à la carte’ modules to match specific needs.
- Deadline for applications: 22 June 2014.
- Eu2P also offers short courses and PhDs. Details of all courses offered as well as information on how to apply can be found on the project website.
There are five projects within IMI’s research training platform aiming to revolutionise education and training to deliver more effective and safe new medicines for patients – EMTRAIN, Eu2P, EUPATI, PharmaTrain, and SafeSciMET.### Collaboration is the key to success and equally important is the projects' ability to reach intended audiences with information to raise awareness and encourage people to get involved in project activities.
Over the next six months these projects will be represented at a variety of European and international conferences through display booths, dedicated sessions or individual presentations. If you are planning to attend any of the following events, please take the opportunity to stop by and find out what is happening in the IMI training and education programmes and how you can benefit, either from a professional or personal perspective.
A team of students from the Netherlands, Panama and the UK was judged to have submitted the best research proposal during a competition run during a recent Eu2P module, developed by Utrecht University in collaboration with GSK, on pharmacoeconomics.### The students were split into teams and worked on the assignment of writing the research proposal throughout the course; at the end of the module, the teams had to present their proposals to an expert jury during a web-based live session. The challenge was made tougher by the fact that the students were scattered across the globe, and so the teams could not meet in person to work on the assignment. Instead, they kept in touch via e-mail, Skype, and Whatsapp. The winning proposal addressed the economic evaluation of triple therapy in metastatic breast cancer. Team member Zeshan Iqbal, who works in pharmacovigilance for Johnson & Johnson in the UK, described the competition as an 'invaluable experience', explaining that the way the assignment ran through the whole module meant that the team could continuously apply what they were learning in the classes to the assignment. According to Zeshan, picking the Eu2P course was an easy decision. 'The diversity and more importantly the flexibility of the Eu2P course was extremely attractive especially as I have a full time job and a young family,' he explains. So far, the modules have met his expectations, and the level of support has been exceptional, he says. Looking to the future, he is optimistic that the course will help him in his career. 'Doing projects and assignments such as the one we did as a competition allow us to learn and benefit from many different people,' he says. 'This course being under the umbrella of IMI, different universities and companies also gives the course credibility which will also be helpful in my career.'
- Interested in applying for an Eu2P course? View the online course catalogue
IMI Education & Training project Eu2P was awarded an education technology prize in the higher education category at the recent Salon Educatec-Educatice in Paris, France.### The awards, which are supported by the various organisations including the French ministries of education and research, recognise the most innovative education technology initiatives. Eu2P’s courses are delivered via distance learning, and students have the option to study for certificates, Master’s degrees, or even a PhD in the evaluation of the benefits and risks of medicines. Elsewhere, the project’s efforts have also been recognised by the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), a collaborative scientific network coordinated by the European Medicines Agency.
- Read Bordeaux Segalen University’s press release about the award (in French)
Applications open on 3 September for the Eu2P PhD programme in pharmacovigilance and pharmacoepidemiology. Applicants are expected to have a postgraduate diploma and a solid background in public health###, especially in pharmacovigilance and pharmacoepidemiology. Candidates will initially be selected on the basis of their academic profile and grades; their professional profile and experience; their English proficiency; their scientific activities; and their letters of reference. Those who pass this first round will be invited to an interview during which they will be judged on their research project synopsis and their oral performance. The deadline for applications is 10 December 2012.
IMI Education& Training project Eu2P is now accepting applications for the next academic year for its certificate programmes and for Year 2 of its joint Eu2P Master in pharmacovigilance and pharmacoepidemiology.### The deadline for applications is 24 June 2012. The courses are delivered online and qualifications are awarded jointly by the academic partners in the project. The Eu2P Master course covers medicines risk identification and quantification; medicines and public health; medicine risk communication; assessing the benefits of medicines; and regulatory processes. Currently, 10 students are following the Year 2 Master programme that began in autumn 2011; the students, who come from all over the world, are mostly already working in the pharmaceutical sector. Scholarships have been awarded to four of the students to facilitate access to the course.
IMI Education & Training project Eu2P has launched its online application tool for its Certificate and Master courses in pharmacovigilance and pharmacoepidemiology.### Certificates are available in a wide range of subject areas and run over 9 weeks (for a standard certificate) or 18 weeks (for an extended certificate). The Masters course offers six curricula that address the professional needs of key specialisations in pharmacovigilance and pharmacoepidemiology. The application period runs until 20 June for the Masters course and 19 August for the Certificates. The first courses will start in September this year. Courses are delivered largely online using interactive web technologies. In 2011, the Masters course is only open to people wishing to embark directly on the Master Year 2. Applications for the Master Year 1 and the Eu2P PhD programme will be launched in April 2012.
BIOVISION and the IMI Education & Training projects
IMI and the IMI Education & Training projects participated in BIOVISION - the World Life Sciences Forum, which was held in Lyon, France, on March 24-26 2013. It is the place where key stakeholders ###debate the impact of the latest scientific advances on society and share their vision on how to overcome health, environment and nutrition challenges. IMI Executive Director Michel Goldman participated in the plenary session ‘How to make better use of collective intelligence’. Mike Hardman, project coordinator of EMTRAIN, represented IMI and the IMI E&T projects in the BIOVISION Investor Conference workshop. Moreover, the IMI E&T projects organised a satellite event on ‘Training and Education in Europe’ where they presented their activities to the forum’s participants at a booth in the exhibition area.
Check out the IMI Education & Training projects’ video
Four of IMI’s Education & Training projects have put together a short video on their activities.###In the six-minute clip, the coordinators of the EMTRAIN, SafeSciMET, Eu2P, and PharmaTrain projects present their courses and the benefits they offer for students and course providers alike. The film also features a presentation by IMI Executive Director Michel Goldman.
ParticipantsShow participants on map
- Almirall SA, Barcelona, Spain
- Amgen, Brussels, Belgium
- Astrazeneca AB, Södertälje, Sweden
- Bayer Pharma AG, Berlin, Germany
- Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany
- Eli Lilly And Company LTD, Basingstoke, United Kingdom
- F. Hoffmann-La Roche AG, Basel, Switzerland
- Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
- H. Lundbeck As, Valby, Denmark
- Janssen Pharmaceutica Nv, Beerse, Belgium
- Novartis Pharma AG, Basel, Switzerland
- Novo Nordisk A/S, Bagsvaerd, Denmark
- Orion Oyj, Espoo, Finland
- Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
- UCB Pharma SA, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
- Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
- Fundacio' Institut Català de Farmacologia, Barcelona, Spain
- Karolinska Institutet, Stockholm, Sweden
- The European Medicines Agency, Canary Wharf, London, United Kingdom
- The University Of Hertfordshire Higher Education Corporation, Hatfield. Hertfordshire, United Kingdom
- Universita Degli Studi Di Verona, Verona, Italy
- Universite De Bordeaux, Bordeaux, France
- Universiteit Utrecht, Utrecht, Netherlands
- Centre Technologique Nouvelle-Aquitaine Composites & Materiaux Avances, Pessac, France
Non EFPIA companies
- Agence nationale de sécurité du médicament et des produits de santé, Saint-Denis Cedex, France
|Name||EU funding in €|
|Agence nationale de sécurité du médicament et des produits de santé||9 600|
|Erasmus Universitair Medisch Centrum Rotterdam||261 084|
|Fundacio' Institut Català de Farmacologia||512 338|
|Karolinska Institutet||9 600|
|The European Medicines Agency||29 889|
|The University Of Hertfordshire Higher Education Corporation||261 084|
|Universita Degli Studi Di Verona||36 219|
|Universite De Bordeaux||680 055|
|Universiteit Utrecht||261 084|
|Name||Funding in €|
|Centre Technologique Nouvelle-Aquitaine Composites & Materiaux Avances||1 647 272|
|Total Cost||3 708 225|